Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Table 3 Drug-related AEs during VEM1-IPI

Event, n (%)^a	VEM1-IPI (n = 46)
	Any Grade	Grade 3	Grade 4
Any drug-related AE	43 (93.5)	27 (58.7)	3 (6.5)
AEs occurring in ≥ 3 patients^b
Rash	28 (60.9)	9 (19.6)	0 (0)
Diarrhea	17 (37.0)	5 (10.9)	0 (0)
AST increased	9 (19.6)	3 (6.5)	1 (2.2)
ALT increased	8 (17.4)	4 (8.7)	0 (0)
Squamous cell carcinoma^c	3 (6.5)	3 (6.5)	0 (0)
Any drug-related serious AEs	18 (39.1)	15 (32.6)	2 (4.3)
AEs leading to discontinuation of treatment	16 (34.8)	9 (19.6)	1 (2.2)

AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, IPI ipilimumab, VEM vemurafenib
^aPatients may have experienced more than 1 event
^bOnly toxicities that reached Grade 3/4 in severity in ≥ 3 patients are presented
^cSquamous cell carcinoma was classified as a serious adverse event (SAE) and was the only SAE that was observed in 3 or more patients (n = 3, grade 3 events)